Cassava Sciences, Inc. (SAVA)
Cassava Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $1.32, up 2.33% on the session, giving a market capitalisation of $63.8M. On trailing twelve-month figures it carries a trailing P/E of -1.52, a net margin of 0.0%. Its beta of -0.84 implies it has historically moved less than the broad market.
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.
Cassava Sciences, Inc. is most often compared with the following Healthcare names: